Kostas Biliouris
Stock Analyst at Oppenheimer
(0.79)
# 3,994
Out of 5,169 analysts
65
Total ratings
30.19%
Success rate
-16.37%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Kostas Biliouris
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PRME Prime Medicine | Initiates: Outperform | $11 | $3.71 | +196.50% | 2 | Mar 12, 2026 | |
| PEPG PepGen | Initiates: Outperform | $15 | $5.09 | +194.70% | 1 | Feb 25, 2026 | |
| KRRO Korro Bio | Upgrades: Outperform | $22 | $12.31 | +78.72% | 4 | Jan 28, 2026 | |
| CNTA Centessa Pharmaceuticals | Maintains: Outperform | $40 → $62 | $28.95 | +114.16% | 7 | Dec 10, 2025 | |
| SRPT Sarepta Therapeutics | Upgrades: Outperform | $50 | $16.84 | +196.91% | 9 | Sep 22, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Outperform | $450 → $470 | $320.42 | +46.68% | 6 | Sep 8, 2025 | |
| IONS Ionis Pharmaceuticals | Upgrades: Outperform | $40 → $70 | $72.33 | -3.22% | 3 | Sep 3, 2025 | |
| JSPR Jasper Therapeutics | Downgrades: Market Perform | $15 → $4 | $1.25 | +220.00% | 1 | Jul 8, 2025 | |
| RCKT Rocket Pharmaceuticals | Maintains: Outperform | $30 → $8 | $4.63 | +72.79% | 2 | May 28, 2025 | |
| DYN Dyne Therapeutics | Initiates: Outperform | $50 | $18.66 | +167.95% | 1 | Mar 12, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $67 → $25 | $6.91 | +261.79% | 2 | Mar 4, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $70 → $50 | $13.48 | +270.92% | 6 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Outperform | $34 | $6.93 | +390.62% | 3 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $22 → $17 | $1.46 | +1,064.38% | 2 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $63 → $40 | $8.61 | +364.58% | 4 | Jul 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $90 | $18.55 | +385.18% | 3 | Jul 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $57 | $25.83 | +120.67% | 3 | Mar 27, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Market Perform | $37 | $70.94 | -47.84% | 1 | Jan 31, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Outperform | $102 → $100 | $56.05 | +78.41% | 4 | Nov 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Outperform | $98 | $50.09 | +95.65% | 1 | Jun 17, 2022 |
Prime Medicine
Mar 12, 2026
Initiates: Outperform
Price Target: $11
Current: $3.71
Upside: +196.50%
PepGen
Feb 25, 2026
Initiates: Outperform
Price Target: $15
Current: $5.09
Upside: +194.70%
Korro Bio
Jan 28, 2026
Upgrades: Outperform
Price Target: $22
Current: $12.31
Upside: +78.72%
Centessa Pharmaceuticals
Dec 10, 2025
Maintains: Outperform
Price Target: $40 → $62
Current: $28.95
Upside: +114.16%
Sarepta Therapeutics
Sep 22, 2025
Upgrades: Outperform
Price Target: $50
Current: $16.84
Upside: +196.91%
Alnylam Pharmaceuticals
Sep 8, 2025
Maintains: Outperform
Price Target: $450 → $470
Current: $320.42
Upside: +46.68%
Ionis Pharmaceuticals
Sep 3, 2025
Upgrades: Outperform
Price Target: $40 → $70
Current: $72.33
Upside: -3.22%
Jasper Therapeutics
Jul 8, 2025
Downgrades: Market Perform
Price Target: $15 → $4
Current: $1.25
Upside: +220.00%
Rocket Pharmaceuticals
May 28, 2025
Maintains: Outperform
Price Target: $30 → $8
Current: $4.63
Upside: +72.79%
Dyne Therapeutics
Mar 12, 2025
Initiates: Outperform
Price Target: $50
Current: $18.66
Upside: +167.95%
Mar 4, 2025
Maintains: Outperform
Price Target: $67 → $25
Current: $6.91
Upside: +261.79%
Jan 10, 2025
Maintains: Outperform
Price Target: $70 → $50
Current: $13.48
Upside: +270.92%
Jan 10, 2025
Upgrades: Outperform
Price Target: $34
Current: $6.93
Upside: +390.62%
Aug 15, 2024
Maintains: Outperform
Price Target: $22 → $17
Current: $1.46
Upside: +1,064.38%
Jul 18, 2024
Maintains: Outperform
Price Target: $63 → $40
Current: $8.61
Upside: +364.58%
Jul 3, 2024
Maintains: Outperform
Price Target: $90
Current: $18.55
Upside: +385.18%
Mar 27, 2024
Maintains: Outperform
Price Target: $57
Current: $25.83
Upside: +120.67%
Jan 31, 2024
Initiates: Market Perform
Price Target: $37
Current: $70.94
Upside: -47.84%
Nov 3, 2023
Maintains: Outperform
Price Target: $102 → $100
Current: $56.05
Upside: +78.41%
Jun 17, 2022
Initiates: Outperform
Price Target: $98
Current: $50.09
Upside: +95.65%